Filing Details

Accession Number:
0001209191-22-047353
Form Type:
4
Zero Holdings:
No
Publication Time:
2022-08-24 16:47:01
Reporting Period:
2022-08-23
Accepted Time:
2022-08-24 16:47:01
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1806310 Taysha Gene Therapies Inc. TSHA () 4
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1793412 Kamran Alam C/O Taysha Gene Therapies, Inc.
3000 Pegasus Park Drive, Ste 1430
Dallas TX 75247
Chief Financial Officer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2022-08-23 3,325 $3.47 266,121 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Direct
Footnotes
  1. The sales reported in this Form 4 represents shares required to be sold by the Reporting Person to satisfy tax withholding obligations in connection with the settlement of restricted stock units. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a "sell to cover" transaction pursuant to a Rule 10b5-1 trading plan.
  2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.40 to $3.58 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (2).